Baseline patient characteristics and prognostic indicators
| Patient ID . | Sex . | Age at diagnosis, y . | Binet stage at diagnosis . | Cytogenetic analysis . | Lymphocyte count, ×109/L . | CD38 . | sIgM . | ZAP-70 . | CD160, % . | Assay performed . |
|---|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | M | 43 | B | Monoallelic 13q−, 11q− | 256.7 | + | + | + | 80 | CS ThI |
| CLL-2 | F | 64 | A | Monoallelic 13q− | 45.1 | − | + | − | 88 | ThI |
| CLL-3 | F | 65 | A | Monoallelic 13q− | 112.3 | − | + | − | 31 | ThI |
| CLL-4 | M | 79 | B | Biallelic 13q− | 78 | − | + | − | 70 | ThI |
| CLL-5 | M | 56 | A | 12+, biallelic 13q− | 116.4 | + | + | + | 46 | ThI |
| CLL-6 | M | 41 | A | Monoallelic & biallelic 13q− | 31.8 | + | + | − | 89 | ThI |
| CLL-7 | M | 50 | A | Monoallelic & biallelic 13q− | 99 | − | + | − | 80 | ThI |
| CLL-8 | M | 60 | A | Monoallelic 13q− | 96.9 | + | − | − | 91 | ThI |
| CLL-9 | M | 48 | A | 11q− | 110 | + | + | − | 42 | ThI |
| CLL-10 | F | 59 | B | 17p− | 424.8 | + | + | − | 73 | CS ThI |
| CLL-11 | M | 69 | B | Monoallelic 13q−, 11q− | 100.5 | + | + | − | 46 | CS ThI |
| CLL-12 | M | 46 | A | Normal | 71.2 | − | +* | − | 97 | CR Ki ThI |
| CLL-13 | F | 67 | A | +12 | 31 | + | + | − | 76 | CR MMP ThI |
| CLL-14 | M | 51 | A | Normal | 72.2 | − | + | − | 26 | ThI |
| CLL-15 | M | 38 | B | 11q−, 17p−, monoallelic 13q− | 76.8 | + | + | + | 71 | CS ThI |
| CLL-16 | M | 51 | A | Monoallelic 13q−, 11q− | 114 | − | + | − | 36 | CS ThI |
| CLL-17 | F | 71 | A | Monoallelic 13q− | 75.5 | + | + | + | 72 | CS ThI |
| CLL-18 | F | 50 | A | Normal | 67.2 | − | + | − | 80 | CS ThI |
| CLL-19 | M | 51 | C | Monoallelic & biallelic 13q− | 216.3 | − | − | − | 62 | ThI |
| CLL-20 | F | 56 | A | Monoallelic 13q−, 11q− | 91.9 | − | + | + | 50 | ThI |
| CLL-21 | M | 58 | B | Biallelic 13q− | 91.2 | + | + | − | 80 | ThI |
| CLL-22 | M | 48 | A | Normal | 113.5 | + | + | + | 43 | ThI |
| CLL-23 | F | 65 | A | Monoallelic 13q− | 89.9 | − | + | − | 91 | Ca Sur Wort |
| CLL-24 | F | 76 | A | Normal | 77 | + | + | + | 30 | Sur WB |
| CLL-25 | M | 56 | B | 6q− | 83.9 | − | + | + | 44 | Sur |
| CLL-26 | M | 56 | A | 11q−, 13q− | 32 | − | + | − | 78 | LY MMP WB Wort |
| CLL-27 | M | 54 | A | 17p− | 186 | − | + | − | 66 | Sur |
| CLL-28 | M | 76 | A | Monoallelic 13q−, 17p− | 73.1 | + | + | − | 29 | Sur |
| CLL-29 | F | 68 | A | Normal | 84.7 | + | + | − | 74 | Sur |
| CLL-30 | M | 77 | A | Monoallelic 13q− | 111.6 | − | + | nt | 36 | Sur CS |
| CLL-31 | M | 63 | A | Monoallelic & biallelic 13q− | 90.4 | + | + | − | 78 | Sur |
| CLL-32 | F | 40 | A | Monoallelic & biallelic 13q− | 193 | − | + | − | 78 | Sur |
| CLL-33 | F | 48 | A | Monoallelic 13q− | 83.6 | − | + | − | 56 | Sur |
| CLL-34 | F | 49 | A | +12 | 52.3 | − | + | − | 54 | Ca Sur WB |
| CLL-35 | M | 48 | A | 11q− | 48 | − | + | − | 64 | Sur |
| CLL-36 | M | 63 | A | Monoallelic & biallelic 13q− | 185.6 | − | + | − | 98 | Ca Sur WB |
| CLL-37 | M | 46 | A | Biallelic 13q− | 40.4 | − | + | − | 81 | Sur WB |
| CLL-38 | F | 50 | A | Monoallelic 13q− | 63.4 | − | + | − | 90 | CR Ki Sur |
| CLL-39 | F | 63 | A | 13q−, 17p− | 196.6 | + | + | − | 30 | CR CS Ki LY Wort |
| CLL-40 | F | 59 | A | Monoallelic 13q− | 134.9 | − | + | − | 95 | MMP |
| CLL-41 | F | 68 | A | Biallelic 13q− | 200 | + | + | Nt | 48 | LY WB Wort |
| CLL-42 | M | 62 | A | 11q−, 13q− | 33 | + | + | − | 46 | CR LY MMP |
| CLL-43 | M | 66 | A | Normal | 27.8 | − | + | + | 43 | Ca CR LY MMP Wort |
| CLL-44 | M | 83 | A | Normal | 58.4 | + | + | NT | 90 | LY Wort |
| CLL-45 | M | 48 | A | Monoallelic 13q− | 235 | + | + | + | 39 | LY Wort |
| CLL-46 | M | 76 | A | Monoallelic 13q− | 37.9 | − | + | Nt | 66 | Ca CR MMP |
| CLL-47 | M | 56 | B | Normal | 71.0 | + | − | + | 89 | Ca CR |
| CLL-48 | F | 63 | B | Normal | 31.9 | Borderline | +* | Nt | 40 | Ca |
| CLL-49 | M | 51 | A | 11q−, 13q− | 41.1 | + | + | − | 26 | Ca Sur |
| CLL-50 | M | 59 | B | 13q−, 17p− | 90 | Nt | Nt | Nt | Nt | WB |
| CLL-51 | M | 68 | A | Monoallelic 13q− | 55.6 | − | + | + | 29 | MMP Sur |
| CLL-52 | M | 49 | A | Monoallelic 13q− | 68.8 | − | + | Nt | 96 | WB |
| CLL-53 | M | 57 | A | NT | 83 | − | + | Nt | 54 | WB |
| CLL-54 | M | 75 | A | +12 | 67 | + | +† | Nt | 27 | CS |
| Patient ID . | Sex . | Age at diagnosis, y . | Binet stage at diagnosis . | Cytogenetic analysis . | Lymphocyte count, ×109/L . | CD38 . | sIgM . | ZAP-70 . | CD160, % . | Assay performed . |
|---|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | M | 43 | B | Monoallelic 13q−, 11q− | 256.7 | + | + | + | 80 | CS ThI |
| CLL-2 | F | 64 | A | Monoallelic 13q− | 45.1 | − | + | − | 88 | ThI |
| CLL-3 | F | 65 | A | Monoallelic 13q− | 112.3 | − | + | − | 31 | ThI |
| CLL-4 | M | 79 | B | Biallelic 13q− | 78 | − | + | − | 70 | ThI |
| CLL-5 | M | 56 | A | 12+, biallelic 13q− | 116.4 | + | + | + | 46 | ThI |
| CLL-6 | M | 41 | A | Monoallelic & biallelic 13q− | 31.8 | + | + | − | 89 | ThI |
| CLL-7 | M | 50 | A | Monoallelic & biallelic 13q− | 99 | − | + | − | 80 | ThI |
| CLL-8 | M | 60 | A | Monoallelic 13q− | 96.9 | + | − | − | 91 | ThI |
| CLL-9 | M | 48 | A | 11q− | 110 | + | + | − | 42 | ThI |
| CLL-10 | F | 59 | B | 17p− | 424.8 | + | + | − | 73 | CS ThI |
| CLL-11 | M | 69 | B | Monoallelic 13q−, 11q− | 100.5 | + | + | − | 46 | CS ThI |
| CLL-12 | M | 46 | A | Normal | 71.2 | − | +* | − | 97 | CR Ki ThI |
| CLL-13 | F | 67 | A | +12 | 31 | + | + | − | 76 | CR MMP ThI |
| CLL-14 | M | 51 | A | Normal | 72.2 | − | + | − | 26 | ThI |
| CLL-15 | M | 38 | B | 11q−, 17p−, monoallelic 13q− | 76.8 | + | + | + | 71 | CS ThI |
| CLL-16 | M | 51 | A | Monoallelic 13q−, 11q− | 114 | − | + | − | 36 | CS ThI |
| CLL-17 | F | 71 | A | Monoallelic 13q− | 75.5 | + | + | + | 72 | CS ThI |
| CLL-18 | F | 50 | A | Normal | 67.2 | − | + | − | 80 | CS ThI |
| CLL-19 | M | 51 | C | Monoallelic & biallelic 13q− | 216.3 | − | − | − | 62 | ThI |
| CLL-20 | F | 56 | A | Monoallelic 13q−, 11q− | 91.9 | − | + | + | 50 | ThI |
| CLL-21 | M | 58 | B | Biallelic 13q− | 91.2 | + | + | − | 80 | ThI |
| CLL-22 | M | 48 | A | Normal | 113.5 | + | + | + | 43 | ThI |
| CLL-23 | F | 65 | A | Monoallelic 13q− | 89.9 | − | + | − | 91 | Ca Sur Wort |
| CLL-24 | F | 76 | A | Normal | 77 | + | + | + | 30 | Sur WB |
| CLL-25 | M | 56 | B | 6q− | 83.9 | − | + | + | 44 | Sur |
| CLL-26 | M | 56 | A | 11q−, 13q− | 32 | − | + | − | 78 | LY MMP WB Wort |
| CLL-27 | M | 54 | A | 17p− | 186 | − | + | − | 66 | Sur |
| CLL-28 | M | 76 | A | Monoallelic 13q−, 17p− | 73.1 | + | + | − | 29 | Sur |
| CLL-29 | F | 68 | A | Normal | 84.7 | + | + | − | 74 | Sur |
| CLL-30 | M | 77 | A | Monoallelic 13q− | 111.6 | − | + | nt | 36 | Sur CS |
| CLL-31 | M | 63 | A | Monoallelic & biallelic 13q− | 90.4 | + | + | − | 78 | Sur |
| CLL-32 | F | 40 | A | Monoallelic & biallelic 13q− | 193 | − | + | − | 78 | Sur |
| CLL-33 | F | 48 | A | Monoallelic 13q− | 83.6 | − | + | − | 56 | Sur |
| CLL-34 | F | 49 | A | +12 | 52.3 | − | + | − | 54 | Ca Sur WB |
| CLL-35 | M | 48 | A | 11q− | 48 | − | + | − | 64 | Sur |
| CLL-36 | M | 63 | A | Monoallelic & biallelic 13q− | 185.6 | − | + | − | 98 | Ca Sur WB |
| CLL-37 | M | 46 | A | Biallelic 13q− | 40.4 | − | + | − | 81 | Sur WB |
| CLL-38 | F | 50 | A | Monoallelic 13q− | 63.4 | − | + | − | 90 | CR Ki Sur |
| CLL-39 | F | 63 | A | 13q−, 17p− | 196.6 | + | + | − | 30 | CR CS Ki LY Wort |
| CLL-40 | F | 59 | A | Monoallelic 13q− | 134.9 | − | + | − | 95 | MMP |
| CLL-41 | F | 68 | A | Biallelic 13q− | 200 | + | + | Nt | 48 | LY WB Wort |
| CLL-42 | M | 62 | A | 11q−, 13q− | 33 | + | + | − | 46 | CR LY MMP |
| CLL-43 | M | 66 | A | Normal | 27.8 | − | + | + | 43 | Ca CR LY MMP Wort |
| CLL-44 | M | 83 | A | Normal | 58.4 | + | + | NT | 90 | LY Wort |
| CLL-45 | M | 48 | A | Monoallelic 13q− | 235 | + | + | + | 39 | LY Wort |
| CLL-46 | M | 76 | A | Monoallelic 13q− | 37.9 | − | + | Nt | 66 | Ca CR MMP |
| CLL-47 | M | 56 | B | Normal | 71.0 | + | − | + | 89 | Ca CR |
| CLL-48 | F | 63 | B | Normal | 31.9 | Borderline | +* | Nt | 40 | Ca |
| CLL-49 | M | 51 | A | 11q−, 13q− | 41.1 | + | + | − | 26 | Ca Sur |
| CLL-50 | M | 59 | B | 13q−, 17p− | 90 | Nt | Nt | Nt | Nt | WB |
| CLL-51 | M | 68 | A | Monoallelic 13q− | 55.6 | − | + | + | 29 | MMP Sur |
| CLL-52 | M | 49 | A | Monoallelic 13q− | 68.8 | − | + | Nt | 96 | WB |
| CLL-53 | M | 57 | A | NT | 83 | − | + | Nt | 54 | WB |
| CLL-54 | M | 75 | A | +12 | 67 | + | +† | Nt | 27 | CS |
Ca indicates caspase activation; CS, cytokine secretion; CR, cytochrome c release; Ki, Ki67 expression; LY, LY294002 inhibition; MMP, mitochondrial membrane potential; Nt, not tested; Sur, survival; ThI, 3H-thymidine incorporation; WB, Western blot; and Wort, wortmannin inhibition.
Surface immunoglobulin expression IgG.
Surface immunoglobulin expression IgD.